GSK Plc ADR [NYSE: GSK] gained 0.12% on the last trading session, reaching $40.91 price per share at the time. If compared to the average trading volume of 3.49M shares, GSK reached a trading volume of 3015243 in the most recent trading day, which is
GSK Plc ADR [NYSE: GSK] plunged by -$0.35 during the normal trading session on while it closed the day at $39.60. GSK Plc ADR stock has also loss -2.68% of its value over the past 7 days. However, GSK stock has declined by -0.45% in
GSK Plc ADR [NYSE: GSK] stock went on a downward path that fall over -0.46% on Wednesday, amounting to a one-week price decrease of less than -2.05%. The company report on March 16, 2024 at 8:00 AM that Positive RUBY phase III data show potential
GSK Plc ADR [NYSE: GSK] loss -0.60% or -0.25 points to close at $41.54 with a heavy trading volume of 3048389 shares. The company report on March 16, 2024 at 8:00 AM that Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in
GSK Plc ADR [NYSE: GSK] gained 2.25% or 0.96 points to close at $43.58 with a heavy trading volume of 4382185 shares. The company report on March 7, 2024 at 12:00 PM that GSK Doubles COiMMUNITY Grant Funding, Launches Patient Resources, as Adult Vaccination Rates
GSK Plc ADR [NYSE: GSK] price plunged by -0.09 percent to reach at -$0.04. The company report on February 8, 2024 at 7:00 AM that Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease. The
GSK Plc ADR [NYSE: GSK] traded at a high on Thursday, posting a 0.52 gain after which it closed the day’ session at $42.16. The company report on February 8, 2024 at 7:00 AM that Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical
GSK Plc ADR [NYSE: GSK] loss -2.00% or -0.84 points to close at $41.07 with a heavy trading volume of 6593222 shares. The company report on February 8, 2024 at 7:00 AM that Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of
GSK Plc ADR [NYSE: GSK] stock went on an upward path that rose over 2.09% on Monday, amounting to a one-week price increase of more than 6.43%. The company report on January 24, 2024 at 8:00 AM that Elegen and GSK Sign Collaboration and Licensing
GSK Plc ADR [NYSE: GSK] gained 0.90% on the last trading session, reaching $39.44 price per share at the time. The company report on January 24, 2024 at 8:00 AM that Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen’s Cell-Free DNA
© 2024, Powered by Smart TechOne
